激动性抗体刺激TREM2——阿尔茨海默病的新兴治疗选择
综述指出,小胶质细胞在阿尔茨海默病中具有保护性功能,TREM2功能缺失突变损害趋化、吞噬、脂质与能量代谢及存活增殖。已开发激动性抗TREM2抗体以增强保护功能,多个抗体处于早期临床试验,并探索提高血脑屏障转运效率及用PET监测靶点结合。
要点
- TREM2风险变异为功能缺失突变,损害小胶质细胞趋化、吞噬、代谢及存活增殖。
- 激动性抗TREM2抗体旨在增强TREM2等位基因完整患者的保护功能。
- 多个抗TREM2抗体处于早期临床试验,正探索提高血脑屏障转运效率。
核心结论
- 动物模型数据及患者生物标志物研究支持在阿尔茨海默病临床前阶段增强TREM2功能的合理性。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- 迟发性阿尔茨海默病风险基因在小胶质细胞富集或专属表达,功能分析揭示其意外保护作用。
- TREM2风险变异为功能缺失突变,影响趋化、吞噬、脂质与能量代谢及存活增殖。
- 已开发激动性抗TREM2抗体以增强TREM2等位基因完整患者的保护功能,多个抗体处于早期临床试验。
- 当前努力旨在实现抗体更高效跨血脑屏障转运,PET成像可用于监测靶点结合。
关键数值与推荐
- TREM2风险变异为功能缺失突变,损害趋化、吞噬、脂质与能量代谢及存活增殖。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neurodegenerative disorders, including Alzheimer's disease, are associated with microgliosis. Microglia have long been considered to have detrimental roles in Alzheimer's disease. However, functional analyses of genes encoding risk factors that are linked to late-onset Alzheimer's disease, and that are enriched or exclusively expressed in microglia, have revealed unexpected protective functions. One of the major risk genes for Alzheimer's disease is TREM2. Risk variants of TREM2 are loss-of-function mutations affecting chemotaxis, phagocytosis, lipid and energy metabolism, and survival and proliferation. Agonistic anti-TREM2 antibodies have been developed to boost these protective functions in patients with intact TREM2 alleles. Several anti-TREM2 antibodies are in early clinical trials, and current efforts aim to achieve more efficient transport of these antibodies across the blood-brain barrier. PET imaging could be used to monitor target engagement. Data from animal models, and biomarker studies in patients, further support a rationale for boosting TREM2 functions during the preclinical stage of Alzheimer's disease.
引用
- Schlepckow K, Morenas-Rodríguez E, Hong S, et al. Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease. Lancet Neurol. 2023. PMID: 37863592. doi:10.1016/S1474-4422(23)00247-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。